Article Details
Retrieved on: 2021-02-06 00:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
On Feb. 4, the FDA revised the Letter of Authorization for COVID-19 convalescent plasma to limit the authorization to the use of high titer COVID-19 ...
Article found on: www.fda.gov
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here